NYSE

Artivion, Inc. (AORT)

605 Thanks from members

Artivion, Inc. (AORT) displays mixed sentiment and financial volatility in 2026, driven by double-digit revenue growth countered by widening GAAP net losses, lowered full-year guidance, and heavy reliance on expensive debt and earnouts to fund major strategic acquisitions like Endospan.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →